• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Surgery Partners (SGRY) Faces Demand And Debt Pressure, Is The Stock Still Undervalued?

    Simply Wall St·10/25/2026 14:27:29
    語音播報

    Recent commentary on Surgery Partners (SGRY) focuses on weakening procedure volumes, a projected sales decline, and high net-debt-to-EBITDA, along with rising interest costs that raise refinancing questions and help explain current investor caution.

    Surgery Partners’ recent 7-day share price return of 7.8% and 30-day gain of 9.38% suggest some short-term momentum is rebuilding. However, the 1-year total shareholder return has declined 30.92%, pointing to a longer record of investor skepticism around debt and demand risks.

    Compare Surgery Partners’ setup with a curated group of financially stronger peers by reviewing our list of solid balance sheet and fundamentals (24 results), which may be better positioned against refinancing and demand pressures.

    Surgery Partners now trades at a clear discount to both analyst targets and some intrinsic value estimates after a sharp long-term drawdown and a recent bounce. Is that gap mispricing the debt and demand risks, or is it not enough compensation for them?

    Most Popular Narrative: 12% Undervalued

    On the most followed view, Surgery Partners is worth about $17.95 per share compared with the recent $15.75 close. This frames the current discount as a bet on margin repair and better payer mix execution over time.

    Disciplined execution on M&A and portfolio optimization, including accretive acquisitions and potential asset sales or health system partnerships, should enhance margin expansion, accelerate deleveraging, and improve free cash flow conversion, supporting improvements in net margins and long-term earnings power.

    See why 5 investors see Surgery Partners as 12% undervalued.

    Result: Fair Value of $17.95 (UNDERVALUED)

    Still, rising interest costs on a high debt load, along with pressure from weaker procedure volumes or payer mix, could quickly challenge the Surgery Partners recovery story.

    Find out about the key risks to this Surgery Partners narrative.

    Next Steps

    If the mood here feels cautious, that is exactly why digging into the underlying data yourself matters, and doing it sooner helps. To understand what upside others are focusing on, review the 2 key rewards.

    Looking for more investment ideas beyond Surgery Partners?

    You do not need to stop with Surgery Partners. Use fresh screens to spot new opportunities and pressure test your current watchlist before the next move.